View the content of this email online

Vectalys & Flashcell merge and create Flash Therapeutics, a new gene therapy company

Technology dyptique
Flash Therapeutics is a new company developing proprietary RNA-based therapeutics and providing broad lentiviral development, manufacturing expertise and support.

Flash Therapeutics will develop gene and cell-based therapies leveraging its proprietary lentiviral platform and bioproduction technologies, through two complementary business lines:


Development and manufacturing support to companies worldwide pursuing lentiviral delivered therapies;


Therapeutic development based on LentiFlash®, with internal programs for blood and liver diseases, and collaborative projects.

To learn more about Flash Therapeutics

Click Here
Image news PR NL

Press release Flash Therapeutics

Vectalys and FlashCell announced that they have merged to create Flash Therapeutics, a new privately held gene therapy company developing gene and cell therapeutics.

Read more
Image news ASGCT NL

Come and meet us at ASGCT 2018!

If you are attending the ASGCT 2018, we will be delighted to welcome you at booth #615, to talk about your projects and to share scientific data about Flash Therapeutics' lentiviral technology use, manufacturing and their clinical applications.

Read more

Follow us

Twitter Flash Therapeutics LinkedIn Flash Therapeutics Youtube Flash Therapeutics Google + Flash Therapeutics
© Flash Therapeutics 2018

Click here to unsuscribe from the mailing list